Advertisements

Stieva-A

Quick links to important sections

Stieva-A

Advertisements
Advertisements

Method of action: Antiacne, Antitumour

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Stieva-A

Property Description
Active Ingredient Tretinoin (all-trans-retinoic acid)
Form Topical preparation (Cream, Gel, or Lotion)
Pharmacological Class Retinoid, Dermatological Agent
General Purpose Normalizing skin cell growth and promoting skin renewal
Origin Derivative of Vitamin A (Retinol)

Defining Stieva-A: A Retinoid Drug Entity

Stieva-A is a specific trade name for a prescription-only topical medication that contains the single active ingredient Tretinoin, chemically known as all-trans-retinoic acid (ATRA). Tretinoin belongs to the Retinoid pharmacological class, distinguishing it as a potent, biologically active compound. Tretinoin is a derivative of Vitamin A that is chemically identical to a metabolite found naturally in the body, although the pharmaceutical version is synthetically produced for stability and purity. It is clinically recognized for its significant structural impact on the skin's surface.

Tretinoin is recognized as a standard therapeutic option, underscoring its established importance in healthcare. Stieva-A is differentiated by its status as a prescription product intended for adult and adolescent dermatological patients, focusing on conditions involving abnormal skin cell turnover.

Composition, Form, and General Therapeutic Role

Stieva-A is formulated for topical administration, meaning it is designed for direct application to the skin surface. It is available in various dosage forms, typically a cream or a gel, which use different inactive bases to suit various skin types. It is a single-active-ingredient product, focusing solely on the cellular actions of Tretinoin.

The preparation’s general therapeutic purpose is to function as a powerful cell differentiation modulator and keratolytic agent. Tretinoin works at a cellular level by binding to specific nuclear receptors, which helps regulate the growth and maturation of epithelial cells and promotes the accelerated turnover of old surface cells. This mechanism supports skin renewal, which generally helps in clearing existing imperfections and promoting a more even and healthy skin texture.

Regulatory References

  1. World Health Organization (WHO)
  2. [according to WHO]
Advertisements

What side effects are possible with Stieva-A?

Possible side effects and safety information

The safety profile of Stieva-A, a topical retinoid containing Tretinoin, is primarily defined by local dermatological reactions documented in official regulatory sources.

Adverse Reaction Scope

The majority of reported effects fall under Skin and Subcutaneous Tissue Disorders. These reactions are formally classified by frequency in clinical data:

  • Very Common (10% or more): Severe skin irritation, skin dryness, and peeling/scaling/flaking of the skin.
  • Common (1% to 10%): Burning sensation, general redness (erythema), itching (pruritus), skin pain, and increased susceptibility to sunburn.

Serious adverse reactions, though rare, include systemic manifestations of an allergic reaction, such as swelling of the face, lips, or throat, and difficulty breathing.

Timing and Safety Considerations

A distinct, time-related pattern of use is officially noted: an apparent exacerbation of acne may occur during the first few weeks of therapy. Most skin-related adverse reactions typically first appear and may peak around the second and third week of treatment.

The official labeling includes several key safety constraints:

  • Photosensitivity: The medication causes heightened susceptibility to sunlight; exposure to UV light and sunlamps must be minimized.
  • Environmental: Increased irritation may be experienced during exposure to weather extremes like severe wind or cold, and application to sunburned or eczematous skin is not recommended due to risk of severe irritation.
  • Reproductive Constraint: Safety information notes that Tretinoin has shown teratogenic effects in animal studies. Therefore, use during pregnancy or in women of childbearing potential requires specific caution and appropriate risk discussions.

Advertisements

Overdose and Emergency Response

The official regulatory profile for Stieva-A (Tretinoin topical) addresses two distinct exposure scenarios: accidental oral ingestion and excessive topical application. The risk of systemic toxicity from routine topical use is minimal due to negligible percutaneous absorption.

Documented Overdose Presentations and Scope

Exposure Type Documented Manifestations
Excessive Topical Use Severe local irritation, marked redness (erythema), excessive peeling (desquamation), discomfort, and potential swelling or blistering.
Accidental Oral Ingestion Systemic effects mirroring high oral intake of Vitamin A may occur. Symptoms can include headache, flushing, red/sore/cracked lips, stomach discomfort, dizziness, and loss of coordination.

Immediate Actions and When to Seek Urgent Help

Regulatory documents state that applying Stieva-A excessively will not improve efficacy but will increase local toxicity. If severe local irritation occurs and persists, temporary or complete discontinuation of the medication is the advised course of action.

Emergency medical attention is required immediately following confirmed or suspected accidental oral ingestion of the topical preparation. This scenario carries the documented risk of systemic exposure. Furthermore, emergency services must be contacted immediately if life-threatening symptoms such as collapse, seizures, or difficulty breathing occur. No specific antidote is known; management is strictly limited to symptomatic and supportive treatment.

Advertisements

Therapeutic Uses of Stieva-A

What Stieva-A Treats: Main Uses and Benefits

The therapeutic uses of Stieva-A (Tretinoin) are centered on specific dermatological contexts. The medication is commonly used to help with conditions presenting with localized discomfort and provides support that helps ease the overall symptom burden associated with these skin conditions.

Stieva-A is used to help with conditions involving episodic or fluctuating manifestations, including acne vulgaris and the visible effects of chronic sun damage (photoaging). The medication may be part of symptomatic management for clusters that include active inflammatory and non-inflammatory lesions, fine facial wrinkles, and mottled hyperpigmentation.

The cream is used to support patients during episodes of heightened discomfort and may assist with managing symptomatic fluctuations.

Quick Fact: Relief for Textural and Inflammatory Symptoms

The medication may assist with managing symptoms linked to organ-specific functional stress, which is a common feature in acne and rough skin texture. It is applied when appropriate in scenarios where additional management of discomfort is required due to these underlying symptoms. The medication may assist with managing symptoms that create noticeable physiological strain and may help ease the overall symptom load associated with both acne and surface roughness.

Regulatory References

  1. NIH MedlinePlus overview
Advertisements

Eligibility and Restrictions for Use

This section explains the official population eligibility and restriction rules for Stieva-A (Tretinoin topical) based solely on regulatory information found in government-approved drug labels.


Contraindicated Populations

Stieva-A is contraindicated and must not be used by:

  • Pregnant individuals or women who are planning a pregnancy [Source 1.4].
  • Patients with a known hypersensitivity or allergy to tretinoin or any ingredient in the formulation [Source 1.1].

Eligibility by Age and Status

  • Adults are eligible for use under labeled conditions [Source 1.4].
  • Pediatric use is generally limited to those 12 years of age and older for most formulations, or 9 years and older for specific newer formulations [Source 1.2].
  • The safety and efficacy of topical tretinoin in children prior to puberty have not been established [Source 1.4].
  • Women of childbearing potential must use a reliable method of contraception consistently throughout treatment [Source 1.4].
  • For lactating women, the official recommendation states a decision must be made to discontinue breastfeeding or discontinue therapy [Source 1.4].

Condition-Based Restrictions

Application of the medicine is restricted on certain skin conditions:

  • It must not be applied to sunburned skin until the skin is fully recovered, nor to eczematous skin, open lesions, or severely inflamed areas [Source 1.1].
  • Use is generally restricted in patients with a personal or family history of cutaneous epithelioma (skin cancer) [Source 1.4].
Advertisements

What should I know about interactions with other medicines?

The official interaction profile for Stieva-A (Tretinoin topical) is defined primarily by local effects on the skin and minimal systemic absorption. Formal contraindications due to systemic drug-drug interactions are not documented in regulatory labeling.

Interacting Product Categories

Property Official Regulatory Information
Topical Agents (Additive Irritation) Preparations containing peeling agents, such as Benzoyl peroxide, Salicylic acid, Sulfur, and Resorcinol.
Systemic Agents (Photosensitizers) Medications known to increase sensitivity to sunlight, including Thiazides, Tetracyclines, Quinolones, Phenothiazines, and Sulfonamides.

Interaction Constraints and Conditions

Property Official Regulatory Information
Timing Requirements If a combination regimen with other topical irritants is required, the products may be applied at different times of the day. The effects of certain harsh preparations must be allowed to subside before initiating Stieva-A.
Excipient-Based Interactions Concomitant use of topical products with high alcohol concentrations (e.g., astringents, after-shave lotions) or other known topical irritants like spices or lime peels may cause cumulative local irritation.
Skin State Considerations Stieva-A has been reported to cause severe local irritation on skin affected by eczema. Use is restricted on sunburned skin until the patient has fully recovered due to heightened susceptibility to sunlight.

Interaction Profile Summary

The documented interactions are classified as pharmacodynamic, where the combined use of agents produces an additive effect, such as intensified skin irritation or augmented photosensitivity. This profile reflects the lack of documented clinically significant systemic drug-drug interactions, such as those related to CYP enzymes or plasma concentration alterations, which is consistent with the minimal systemic exposure of the topical formulation.

Advertisements

Mechanism of Action

How Stieva-A Works

Stieva-A (Tretinoin) acts exclusively at the molecular and cellular level within the skin structure. Its mechanism is not fast-acting; rather, it is a structural regulator defined by three key biological actions that collectively influence the organization of the epidermis and follicular unit.


Transcriptional Modulation and Gene Control

The mechanism begins as Tretinoin functions as an agonist for Retinoic Acid Receptors ( RARs), predominantly the RARgamma subtype found in the epidermis. This binding forms a complex that directly engages DNA response elements, effectively modulating the gene transcription that governs skin cell behavior.


Normalization of Follicular Cell Turnover

The altered gene expression leads to a profound effect on the Follicular Epithelial Differentiation Pathway. This process accelerates cell turnover and normalizes the growth pattern of keratinocytes, preventing the abnormal adhesion of cells and fundamentally modulating the factors leading to follicular blockage.


Dampening of Sub-Cellular Inflammatory Signaling

In addition to its structural role, Tretinoin influences the regulation of overactive physiological responses by repressing key pro-inflammatory transcription factors like AP-1 and NF-kappa B. This molecular suppression limits the cell’s ability to produce inflammatory cytokines, thus limiting the production of excessive mediator activity within the tissue.

Advertisements

Dosage and Administration Information

Administration Scope and Principles

Stieva-A is formulated strictly for topical application to the skin and must not be administered orally, to the eyes, or near the mouth or other mucous membranes. The standardized regimen specifies use once daily, typically performed in the evening or immediately before bedtime. The area of skin to be treated should be gently cleansed with a mild, non-medicated preparation and patted dry before application.

The dosing protocol is based on coverage rather than volume. A thin layer of the cream, gel, or lotion is applied to the entire affected area. For the facial region, the quantity should be limited to approximately a pea-sized amount, as applying an excessive amount will not increase the medication’s efficacy. It is specified that if significant skin irritation or local intolerance occurs during treatment, the frequency or the amount applied may be temporarily reduced or discontinued entirely as a necessary adjustment.

Therapeutic use generally requires a long-term commitment. While initial changes may be observed sooner, a duration of more than seven weeks of continuous, consistent application is often necessary to achieve and sustain the full effect. Standard use includes approval for adolescent patients; however, the minimum age of approval varies by the specific formulation, generally ranging from 9 to 12 years of age.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Stieva-A


Evidence for use in Acne Vulgaris

Research has primarily examined the active ingredient in Stieva-A for populations with Acne Vulgaris through short-term randomized controlled trials (RCTs). These studies focused on outcomes linked to inflammatory or irritative states of the skin, monitoring how symptoms evolved in the observed populations, which included adults and adolescents diagnosed with common acne.

The findings describe patterns observed in the studies related to the evolution of some acne lesions over defined time intervals. Research highlights measured differences during the study period, such as a measured change in the count of certain types of acne lesions. Evidence remains limited regarding the full range of outcomes, as long-term effects are not fully established, and data for certain groups, such as those with very severe, cystic acne, remain insufficient.


Evidence for use in Fine Wrinkles and Mottled Hyperpigmentation

Research has also explored the active ingredient in Stieva-A in studies focusing on changes in skin appearance, specifically outcomes related to the visibility of fine facial wrinkles and areas of mottled hyperpigmentation (dark spots). The research examined patient-reported outcomes over defined time intervals.

Research contributes to understanding short-term changes, where some studies report how the appearance of fine facial lines and areas of uneven skin tone evolved in the observed populations. This evidence contributes to the broader evidence landscape. However, research is ongoing, the sample sizes were modest in several studies, and comparative evidence against other procedures is lacking.


Long-term Studies and Follow-up

Research exploring short-term symptom changes is more abundant than data focusing on the effects observed over many years. There is limited information for long-term outcomes and sustained skin appearance patterns. Follow-up durations were limited in many initial trials, and while open-label extensions were applied, certainty remains low regarding the consistency and sustainability of findings after many months or years of use.


Evidence in Special Populations

The active ingredient has been evaluated in various adult and adolescent populations, but data for certain groups remain insufficient. Research examining outcomes in very young children or older adults is often limited. Data for patients who are or may become pregnant are restricted due to safety requirements and potential risks; research provides limited information for this specific population.


What is still uncertain about Stieva-A

Evidence quality varies across studies, and data are still emerging across various outcomes. Certainty remains low regarding the consistency of measured responses in individuals with conditions characterized by fluctuating manifestations. Findings were mixed in certain areas, and it is important to acknowledge that subgroup findings are uncertain due to modest sample sizes and limited follow-up durations.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Stieva-A (FAQ)


Q: Do I need a prescription to buy Stieva-A?

Stieva-A (Tretinoin) is classified as a prescription-only topical medication. This means a healthcare professional must authorize its use through a valid prescription before it can be dispensed.


Q: Should I apply a moisturizer before or after Stieva-A?

Official information advises applying Stieva-A to clean, dry skin. Moisturizer is often recommended by doctors to help manage the common side effect of skin irritation. Patients are generally advised to discuss the application sequence for moisturizers with their prescribing doctor.


Q: What kind of studies support the use of Stieva-A for anti-aging?

Clinical studies have investigated the active ingredient in Stieva-A for outcomes related to changes in skin appearance, specifically the mitigation of fine facial wrinkles and areas of mottled hyperpigmentation (dark spots). This evidence contributes to the understanding of its role in addressing these specific changes in skin appearance.


Q: Can I use other retinol products while on Stieva-A?

The use of other topical products, including other retinol derivatives, should be approached with caution due to the possibility of additive skin irritation. Regulatory information indicates that combining products that cause peeling or irritation can increase local side effects. Patients should always consult a healthcare professional before combining topical products.


Q: What is the recommended amount of Stieva-A to use for the entire face?

Official instructions specify that the amount of Stieva-A applied to the entire affected facial area should be limited to approximately a pea-sized amount. Using a larger amount will not increase the medication's effectiveness and may increase the risk of skin irritation.


Q: Can Stieva-A be used for body acne or only on the face?

Stieva-A is indicated for the topical treatment of acne vulgaris and other skin conditions. While the face is the most commonly treated area, patients should discuss the use of Stieva-A on areas other than the face with a healthcare professional.


Q: Are there any specific vitamins or supplements that interact with Stieva-A?

Topical Stieva-A is a derivative of Vitamin A. While regulatory labels for the topical form primarily focus on local skin interactions, taking excessive amounts of oral Vitamin A supplements may increase the risk of side effects similar to those of oral retinoids. Any changes to vitamin or supplement intake should be reviewed with a healthcare professional.


Q: What happens if I accidentally use too much Stieva-A?

Regulatory information indicates that applying Stieva-A excessively will not lead to faster or better results. Instead, it may result in increased redness, peeling, or discomfort. If a large amount is accidentally ingested, it may cause side effects similar to those of excessive oral Vitamin A intake.


Q: Will stopping Stieva-A cause my skin issues to return immediately?

Regulatory documentation suggests that if treatment is discontinued, the mitigating effects of the medication on fine wrinkles, mottled hyperpigmentation, and roughness of facial skin may be lost over time. Sustained results are typically linked to continuous use and adherence to a sun-avoidance regimen.


Q: Can Stieva-A be used if I have sensitive skin?

Tretinoin is a known dermal irritant, and individuals with sensitive skin may experience excessive dryness, redness, or blistering. The regulatory label reports that it can cause severe irritation on eczematous skin. Patients with known skin sensitivity should review the risks of severe irritation with a healthcare professional before use.


Q: Does Stieva-A interact with common anti-acne cleansers?

Yes, regulatory documents warn against the simultaneous use of medicated or abrasive soaps and cleansers. These, along with other topical products containing a strong drying effect or high alcohol content, may cause an additive irritation effect when combined with Stieva-A.


Q: Can Stieva-A be used during the summer months?

Stieva-A causes heightened susceptibility to sunlight (photosensitivity). Unprotected exposure to UV light and sunlamps must be minimized. Patients are advised to minimize sun exposure and use broad-spectrum sunscreen (SPF 15 or higher) and protective clothing as part of their treatment plan, especially during periods of high sun exposure.


Q: Is it normal to feel a tingling or burning sensation after applying Stieva-A?

Yes, official safety information states that a transitory feeling of warmth or a slight stinging may be noted upon application. A general burning sensation is also listed as a common adverse reaction in clinical data, particularly during the initial phase of treatment.


Q: What makeup products should I avoid while using Stieva-A?

While specific makeup brands are not listed, official warnings advise caution with cosmetics that have a strong drying effect, high concentrations of alcohol, or other known topical irritants. Using these products with Stieva-A may cause cumulative local irritation.


Q: Does Stieva-A cause dry patches around the mouth or eyes?

Stieva-A can commonly cause excessive dryness and peeling. Regulatory safety information notes that the product should be kept away from the eyes, mouth, and nasal creases, as irritation, including dry patches, is more likely to occur in these sensitive areas.


Q: Does Stieva-A make your skin thinner over time?

The long-term effects of using Stieva-A for greater than 48 weeks are not definitively established. While regulatory documents note that some long-term histological findings showed changes in skin cells, the significance of these findings is unknown, and the full effects of chronic long-term use are not fully established.


Q: Can men use Stieva-A for skin concerns?

Yes, Stieva-A is indicated for use in adults and adolescents for the topical treatment of acne vulgaris and other indicated conditions. Regulatory labeling does not restrict its use based on gender.


Q: Does Stieva-A work for cystic or hormonal acne?

Stieva-A is indicated for the treatment of acne vulgaris (common acne). Official labels note that data for certain subgroups, such as those with very severe or cystic acne, may be limited. The effectiveness of Stieva-A for purely hormonal acne can be reviewed with a healthcare professional.


Q: What's the difference between Stieva-A cream and Stieva-A gel?

Stieva-A is available in different topical formulations, such as cream and gel. These dosage forms differ primarily in their inactive ingredients. For instance, the gel formulation may have a more drying effect than the cream due to the presence of alcohol.


Q: Can I go swimming or use saunas while treating my skin with Stieva-A?

Regulatory guidance suggests minimizing exposure to excessive heat (like in a sauna) and prolonged sun/UV exposure (like in outdoor swimming) because Stieva-A increases skin sensitivity. Patients should exercise caution and follow sun protection guidelines when engaging in activities with high heat or sun exposure.


Q: What are the signs that Stieva-A is starting to work?

Clinical studies suggest that therapeutic results may be noticed after approximately two weeks of consistent use. However, the full, sustained beneficial effects are generally observed after more than seven weeks of continuous application.


Q: Should I wash my face right before applying Stieva-A?

Official instructions specify that prior to application, the area to be treated should be thoroughly cleansed with a mild, non-medicated preparation and then patted dry. The medication should be applied to dry skin.


Q: Does Stieva-A help with skin discoloration or melasma?

Stieva-A is specifically indicated for the mitigation of mottled hyperpigmentation (dark spots) on the skin. Use for conditions beyond mottled hyperpigmentation, such as melasma, is generally reviewed by a healthcare professional.


Q: What types of ingredients should I look for in a moisturizer when using Stieva-A?

While regulatory labels advise using a topical moisturizer if dryness is bothersome, they do not specify particular ingredients to seek out. Moisturizers are often recommended to help manage dryness and irritation. Using a mild, non-irritating, non-comedogenic formula is generally preferred.


Q: Can I use Stieva-A while having laser hair removal or waxing?

Since Stieva-A is a powerful dermal irritant that increases skin sensitivity and turnover, procedures that cause skin trauma or peeling, such as waxing, chemical peels, or laser hair removal, should be approached with caution. They may increase the risk of severe irritation or skin changes.


Q: Are there any known long-term side effects from using Stieva-A for many years?

The safety of using Tretinoin daily for greater than 48 weeks has not been systematically established in well-controlled trials. The long-term safety profile and the results of chronic irritation on the skin over many years are not fully known based on the initial regulatory studies.


Q: How does Stieva-A affect the skin's barrier function?

The initial redness and irritation commonly experienced when starting Stieva-A are consistent with a temporary compromise of the skin's outer barrier function (stratum corneum). For this reason, using moisturizers is often recommended to help mitigate the resulting dryness and irritation.


Q: Is Stieva-A suitable for mature skin as well as younger skin?

Stieva-A is approved for use in adults and adolescents for acne. However, for certain indications like fine wrinkles, the efficacy of some formulations has not been established in people greater than 50 years of age in the initial clinical studies.

Advertisements

How should Stieva-A be stored and disposed of?

How to Store and Dispose of Stieva-A?

Stieva-A (tretinoin) requires specific storage conditions to maintain the stability of the active ingredient and must be handled and disposed of safely, as directed by official regulatory labeling.


Official Storage and Handling Requirements

  • Temperature: Store at controlled room temperature, generally 20 C to 25 C (68 F to 77 F). Do not allow the product to freeze and keep it away from excessive heat.
  • Protection: The product must be protected from light and moisture. The gel formulation is labeled as flammable and must be kept away from fire or open flames.
  • Container: Keep Stieva-A in its original container with the cap tightly closed when not in use.
  • Child Safety: It is mandatory to store the medicine out of the sight and reach of children.

Official Disposal Instructions

Do not flush unused or expired Stieva-A down the toilet or pour it into a drain, as this violates environmental regulations. Disposal should follow local regulatory guidelines, typically by returning the product to a pharmacy take-back program or following instructions from a healthcare professional.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Stieva-A found in:

A-Z Index: